prediction
If regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.
A prediction by MY READ. Statements are as reported by the cited publishers — not verified by DecisionGateway.
If regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.
Discussion
Related claims
Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.Eli Lilly · statementWhat changes this read: regulators reject the weight-loss-independent analysis, safety or adherence weakens in full publication, or payers restrict coverage despite an approval.MY READ · predictionLilly's analysis attributed 39.6% of the treatment effect to factors beyond weight loss.Lilly · statementNovo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.诺和诺德 · statementLVBI11 has overcome a regulatory barrier and is advancing toward HGLG11.Suno Notícias · statementThe FDA requires a warning about a risk of sudden blindness with popular weight-loss drugs.noticias_telemundo · statement